Company Name | Bayer Taiwan Co., Ltd |
---|---|
Protocol Number | 21460 |
Title of Study | Systemic treatment patterns of hepatocellular carcinoma (HCC) in Taiwan |
Primary Objective | The primary objective is to describe systemic treatment patterns of unresectable HCC patients in Taiwan whose first-line systemic treatment is sorafenib. |
Number of Sites | 1 |
Period of Study | From: to: |
Number of Patients | 415人 |
IRB Approval Date | 2020/08/15 |
Publication Plan / Date | 2022/12/31 |